Palacios J M, Boddeke H W, Pombo-Villar E
Preclinical Research, Sandoz Pharma Ltd., Basle, Switzerland.
Acta Psychiatr Scand Suppl. 1991;366:27-33. doi: 10.1111/j.1600-0447.1991.tb03106.x.
The current status of the pharmacology of central cholinergic transmission is reviewed. Particular attention is paid to the compounds that have been or are potential candidates as therapeutic agents for the treatment of mental disorders, particularly senile dementia. Compounds affecting acetylcholine synthesis, storage and release, affecting the enzyme acetylcholinesterase, acting on nicotinic cholinergic receptors, as well as compounds acting on muscarinic cholinergic receptors are reviewed. It is concluded that the most promising approaches for the development of new therapeutic agents might be specific acetylcholinesterase inhibitors and compounds with specific action at only one of the muscarinic cholinergic receptor subtypes.
本文综述了中枢胆碱能传递药理学的现状。特别关注了那些已成为或有可能成为治疗精神障碍尤其是老年痴呆症治疗药物的化合物。文中对影响乙酰胆碱合成、储存和释放的化合物、影响乙酰胆碱酯酶的化合物、作用于烟碱型胆碱能受体的化合物以及作用于毒蕈碱型胆碱能受体的化合物进行了综述。得出的结论是，开发新型治疗药物最有前景的方法可能是特异性乙酰胆碱酯酶抑制剂以及仅对一种毒蕈碱型胆碱能受体亚型有特异性作用的化合物。
